1. PROPRIETARY & CONFIDENTIAL 1 Specialty Pharmacy Trends and AcariaHealth Specialty Pharmacy Solution AcariaHealth Presentation April 6, 2015

2. PROPRIETARY & CONFIDENTIAL 2 COMPANY OVERVIEW Comprehensive specialty pharmacy servicing all specialty disease states Fully integrated single operating platform Licensed to distribute specialty pharmaceuticals nationally out of 13 locations Medicaid licenses in 46 states Accreditations –The Joint Commission (TJC, formerly Joint Commission on Accreditation of Healthcare Organizations or the JCAHO) –URAC National physician team: –1 National VP, –3 Regional VPs, –33 physician Reps, –20 Provider Experience Managers National Comprehensive Specialty Pharmacy Legend Current LocationsPending Locations

3. PROPRIETARY & CONFIDENTIAL 3 CENTENE OVERVIEW # 186 on the Fortune 500 list WHO WE ARE (CENTENE) $ 21.0-21.3 billion expected revenue for 2015 23 states with government sponsored healthcare programs 5.3 million members - 2015 Medicaid Licensed (46 states) 13 National Pharmacies 11 million members (est) - 2016 St. Louis based company founded in Milwaukee in 1984 WHO WE ARE (ACARIAHEALTH)

4. PROPRIETARY & CONFIDENTIAL 4 COMMITMENT TO CALIFORNIA Strong CA Presence AcariaHealth Locations Client Location US Script Location Over 4,000 California-based employees Fresno: PBM IT operations, Customer Service Center, Finance, Pharmacy Networks, Benefits, Implementation and Networks Commerce: Specialty Pharmacy Sacramento: Specialty Pharmacy, Finance, Data Analysis, Audit & Recovery, Actuarial Services, Trade Relations, Pharmacy Networks, Pharmacy Operations, Formulary and Benefits, Prior Authorization, Clinical Pharmacy Services, Communications, Government Oversight and Audit, Call Center Los Angeles: Prior Authorization, Pharmacy Operations Health Net Location

5. PROPRIETARY & CONFIDENTIAL Confidential & Proprietary © 2016 Envolve. 5 WHO WE ARE

6. PROPRIETARY & CONFIDENTIAL “Biologic, biological, biopharmaceutical” Injected, Infused, Inhaled, Oral Limited / Restricted distribution Typically require specially handling, refrigeration, etc. High-Cost: $1K-$30K / month While there is no standard industry definition for Specialty Pharmaceuticals, they generally include the following characteristics: Clinical specialties Dermatology Gastroenterology Hematology and oncology Infectious diseases Neurology Pediatric endocrinology Rheumatology Transplant WHAT IS SPECIALTY PHARMACY?

7. PROPRIETARY & CONFIDENTIAL 1. “Specialty Drugs Will Account for 50% of All Drug Costs by 2018,” Formulary, June 2013.Specialty Drugs Will Account for 50% of All Drug Costs by 2018 By 2017, 7 of top 10 selling drugs expected to be specialty pharmacy SPECIALTY PHARMACY INDUSTRY TRENDS #150%800+ Pharmaceutical industry growth segment Of drug expenditures forecasted to be for specialty medications by 2018 1 New specialty pharmacy products in the FDA pipeline Specialty Pharmaceutical Revenue 201020142018 $275 B $324 B$475 B

8. PROPRIETARY & CONFIDENTIAL 8 Healthcare Provider Health Plan Case Manager Patient Assistance Program Insurance Verification Coordination by Patient Care Representative Assessments / training by nursing staff Clinical pharmacist oversight / intervention External touch points Specialty Pharmacy Home Infusion Services THE PATIENT EXPERIENCE HIGH TOUCH / CLINICAL FOCUS / OUTCOMES DRIVEN

9. PROPRIETARY & CONFIDENTIAL Hepatitis C Clinical Offering Program: Hepatitis C Therapy Management Waste avoidance due to adherence risk mitigation Oncology Clinical Offering Program: Oncology Therapy Management 91.45% MPR** Innovations in Clinical Services Across Stakeholders HealthPlan – Specialty Pharmacy – Provider – Pharmacy Benefit Manager 9

10. PROPRIETARY & CONFIDENTIAL 10 TRENDS IN PHARMACEUTICAL SPEND Robust PipelineBiosimilarsHepatitis C Coverage Drug Pricing340 B

11. PROPRIETARY & CONFIDENTIAL 11 > 50 % of specialty drugs under development are for cancer DRUG PIPELINE – SIGNIFICANT DEVELOPMENT IN ONCOLOGY

12. PROPRIETARY & CONFIDENTIAL 12 | 1. Congressional Budget Office. Cost Estimate. S 1695. Biologics Price Competition and Innovation Act of 2007. June 25, 2008. Available at: https://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/94xx/doc9496/s1695.pdf. Accessed 9 Sept 2014. BIOSIMILARS SAVINGS – YES BUT HOW MUCH? CBO projects $25 Billion in savings 1 CBO expects $25 Billion reduced total expenditures on biologics over the 2009-2018 period. 1 Over that 10-year period, such savings would equal roughly 0.5 percent 1